Which has preferable valuation & earnings, ELTX or NAUT?

Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A Nautilus Biotechnology N/A N/A -$59M -$0.46 N/A

Is ELTX or NAUT more profitable?

Nautilus Biotechnology's return on equity of -35.04% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Nautilus Biotechnology N/A -35.04% -29.16%

Which has better valuation and earnings, ELTX or IMRX?

Immuneering is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is ELTX or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Immuneering N/A -31.93% -29.92%

Does the media prefer ELTX or IMRX?

In the previous week, Elicio Therapeutics had 6 more articles in the media than Immuneering. MarketBeat recorded 7 mentions for Elicio Therapeutics and 1 mentions for Immuneering. Elicio Therapeutics' average media sentiment score of 0.38 beat Immuneering's score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ELTX or SABS more profitable?

SAB Biotherapeutics' return on equity of -0.29% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% SAB Biotherapeutics N/A -0.29% -0.25%

Is ELTX or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Does the media prefer ELTX or ZNTL?

In the previous week, Elicio Therapeutics had 6 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Elicio Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Elicio Therapeutics' average media sentiment score of 0.38 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Elicio Therapeutics (ELTX) Competitors

$3.22 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.22 0.00 (-0.03%)

As of 07/2/2026 07:58 PM Eastern

Compare

ELTX vs. NAUT, IMRX, SABS, TRDA, and ZNTL

Should you buy Elicio Therapeutics stock or one of its competitors? MarketBeat compares Elicio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elicio Therapeutics include Nautilus Biotechnology (NAUT), Immuneering (IMRX), SAB Biotherapeutics (SABS), Entrada Therapeutics (TRDA), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "med - biomed/gene" industry.

How does Elicio Therapeutics compare to Nautilus Biotechnology?

Elicio Therapeutics (NASDAQ:ELTX) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Elicio Therapeutics had 7 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 7 mentions for Elicio Therapeutics and 0 mentions for Nautilus Biotechnology. Elicio Therapeutics' average media sentiment score of 0.38 beat Nautilus Biotechnology's score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Neutral
Nautilus Biotechnology	Neutral

Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Elicio Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Nautilus Biotechnology's return on equity of -35.04% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 513.35%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 131.21%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Elicio Therapeutics beats Nautilus Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Immuneering?

Elicio Therapeutics (NASDAQ:ELTX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Immuneering's return on equity of -31.93% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Immuneering	N/A	-31.93%	-29.92%

Elicio Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Elicio Therapeutics had 6 more articles in the media than Immuneering. MarketBeat recorded 7 mentions for Elicio Therapeutics and 1 mentions for Immuneering. Elicio Therapeutics' average media sentiment score of 0.38 beat Immuneering's score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 513.35%. Immuneering has a consensus target price of $16.50, suggesting a potential upside of 217.92%. Given Elicio Therapeutics' higher probable upside, equities research analysts plainly believe Elicio Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Elicio Therapeutics beats Immuneering on 7 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to SAB Biotherapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Elicio Therapeutics presently has a consensus price target of $19.75, suggesting a potential upside of 513.35%. SAB Biotherapeutics has a consensus price target of $12.00, suggesting a potential upside of 206.12%. Given Elicio Therapeutics' higher possible upside, equities research analysts plainly believe Elicio Therapeutics is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Elicio Therapeutics had 7 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for Elicio Therapeutics and 0 mentions for SAB Biotherapeutics. Elicio Therapeutics' average media sentiment score of 0.38 beat SAB Biotherapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Neutral
SAB Biotherapeutics	Neutral

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SAB Biotherapeutics has higher revenue and earnings than Elicio Therapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
SAB Biotherapeutics	$1.32M	227.06	$13.27M	-$2.11	N/A

Elicio Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

SAB Biotherapeutics' return on equity of -0.29% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

Elicio Therapeutics and SAB Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Elicio Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.79	-$143.75M	-$3.99	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

In the previous week, Elicio Therapeutics had 7 more articles in the media than Entrada Therapeutics. MarketBeat recorded 7 mentions for Elicio Therapeutics and 0 mentions for Entrada Therapeutics. Elicio Therapeutics' average media sentiment score of 0.38 beat Entrada Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
Elicio Therapeutics	Neutral

Entrada Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Entrada Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 126.68%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 513.35%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Elicio Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Summary

Elicio Therapeutics beats Entrada Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Elicio Therapeutics compare to Zentalis Pharmaceuticals?

Elicio Therapeutics (NASDAQ:ELTX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

35.0% of Elicio Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Elicio Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

In the previous week, Elicio Therapeutics had 6 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Elicio Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Elicio Therapeutics' average media sentiment score of 0.38 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elicio Therapeutics presently has a consensus target price of $19.75, suggesting a potential upside of 513.35%. Zentalis Pharmaceuticals has a consensus target price of $5.83, suggesting a potential upside of 30.79%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Elicio Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Zentalis Pharmaceuticals' return on equity of -53.61% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Elicio Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A

Summary

Elicio Therapeutics beats Zentalis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.46M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.34	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	35.78	8.66	10.96	6.46
Net Income	-$39.57M	$23.81M	$3.57B	$337.01M
7 Day Performance	-19.30%	3.39%	2.12%	1.69%
1 Month Performance	-75.72%	10.81%	5.25%	3.81%
1 Year Performance	-59.29%	62.61%	33.29%	23.90%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	3.2201 of 5 stars	$3.22 flat	$19.75 +513.4%	-59.3%	$61.46M	N/A	N/A	N/A	Gap Up
NAUT Nautilus Biotechnology	2.9905 of 5 stars	$2.27 -3.8%	$4.00 +76.2%	+110.5%	$299.91M	N/A	N/A	130
IMRX Immuneering	2.569 of 5 stars	$4.53 -1.5%	$16.50 +264.2%	+53.1%	$297.61M	N/A	N/A	60	Positive News
SABS SAB Biotherapeutics	2.7023 of 5 stars	$3.87 +0.8%	$12.00 +210.1%	+126.6%	$293.62M	$1.32M	N/A	140
TRDA Entrada Therapeutics	2.763 of 5 stars	$7.15 -5.2%	$17.50 +144.8%	+6.7%	$292.71M	$25.42M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. NAUT, IMRX, SABS, TRDA, and ZNTL

How does Elicio Therapeutics compare to Nautilus Biotechnology?

Summary

How does Elicio Therapeutics compare to Immuneering?

Summary

How does Elicio Therapeutics compare to SAB Biotherapeutics?

Summary

How does Elicio Therapeutics compare to Entrada Therapeutics?

Summary

How does Elicio Therapeutics compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. NAUT, IMRX, SABS, TRDA, and ZNTL

How does Elicio Therapeutics compare to Nautilus Biotechnology?

Does the media prefer ELTX or NAUT?

Which has preferable valuation & earnings, ELTX or NAUT?

Which has more risk & volatility, ELTX or NAUT?

Is ELTX or NAUT more profitable?

Do analysts prefer ELTX or NAUT?

Do insiders and institutionals have more ownership in ELTX or NAUT?

Summary

How does Elicio Therapeutics compare to Immuneering?

Is ELTX or IMRX more profitable?

Which has more volatility and risk, ELTX or IMRX?

Do institutionals and insiders have more ownership in ELTX or IMRX?

Does the media prefer ELTX or IMRX?

Which has better valuation and earnings, ELTX or IMRX?

Do analysts rate ELTX or IMRX?

Summary

How does Elicio Therapeutics compare to SAB Biotherapeutics?

Do analysts rate ELTX or SABS?

Does the media prefer ELTX or SABS?

Do institutionals & insiders hold more shares of ELTX or SABS?

Which has higher earnings & valuation, ELTX or SABS?

Which has more risk & volatility, ELTX or SABS?

Is ELTX or SABS more profitable?

Summary

How does Elicio Therapeutics compare to Entrada Therapeutics?

Which has stronger earnings & valuation, TRDA or ELTX?

Does the media favor TRDA or ELTX?

Which has more volatility and risk, TRDA or ELTX?

Do analysts recommend TRDA or ELTX?

Do insiders & institutionals hold more shares of TRDA or ELTX?

Is TRDA or ELTX more profitable?

Summary

How does Elicio Therapeutics compare to Zentalis Pharmaceuticals?

Do insiders and institutionals have more ownership in ELTX or ZNTL?

Which has more volatility & risk, ELTX or ZNTL?

Does the media prefer ELTX or ZNTL?

Do analysts prefer ELTX or ZNTL?

Is ELTX or ZNTL more profitable?

Which has stronger earnings & valuation, ELTX or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools